RecruitMe Clinical Trial

RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MTAU9937A IN PATIENTS WITH PRODROMAL-TO-MILD OR MODERATE ALZHEIMER'S DISEASE
Efficacy and Safety Study of Drug (MTAU9937A) in Patients with Alzheimer's Disease Preclinical-to-Mild or Moderate Alzheimer's Disease
Sponsor:Genentech, Inc.
Enrolling:Male and Female Patients
Age Range:Between 50 and 85 years old
IRB Number:AAAR6047
U.S. Government ID:NCT03289143
Contact: Katrina Cuasay: 212-305-2371 / kc2305@cumc.columbia.edu
Additional Study Information:

This is a Phase II, randomized, double-blind, placebo-controlled, parallel-group study that will evaluate the efficacy, safety and tolerability, pharmacokinetics, and pharmacodynamics of the study drug (an antibody to the tau protein called MTAU9937A) in patients with prodromal or mild Alzheimer's disease. The study consists of a screening period, a double-blind treatment period, an optional open-label extension (OLE) period, and a safety follow-up period.

This study is closed
Investigator
Lawrence Honig, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Katrina Cuasay
Email: kc2305@cumc.columbia.edu
Phone: 212-305-2371